Visionary Holdings and Yike Form Joint Venture to Advance Stem Cell Therapy for Diabetes Remission

Introduction to Visionary Holdings and Yike

On October 22, 2025, Visionary Holdings Inc., known as "GV" and publicly listed on Nasdaq under the symbol GV, announced a groundbreaking partnership with Jiangsu Yike Regenerative Medical Technology Co., Ltd. The formation of a new joint venture, Visionary Yike Stemcell Technologies Inc., aims to drive global commercialization of innovative stem cell therapy aimed at diabetes remission. This initiative represents a significant step into a potentially lucrative market valued at approximately $150 billion.

Establishing the Joint Venture

This strategic cooperation agreement marks an important milestone for both companies as they combine their respective strengths in regenerative medicine and global commercialization. GV intends to utilize its facility located at 95-105 Moatfield Drive, Toronto, which once served as the headquarters for IBM, to house the new venture. Spanning over 40,000 square meters, this property is under consideration to be developed further, with plans for cleanrooms, biostorage facilities, and related infrastructures that will support the joint venture's operations.

In focusing on areas like stem cell therapy, immune cell engineering, and AI-supported diagnostics, the partnership plans to leverage Yike's proprietary technologies alongside GV's expansive market infrastructure. GV will hold an 85% interest in the joint venture, while Yike retains 15%. Together, they will advance the clinical applications and commercialization efforts of Yike's promising stem cell technologies aimed at treating both Type 1 and Type 2 diabetes. This groundbreaking approach has demonstrated early potential in preclinical studies, suggesting that the partnership could yield significant advancements in diabetes treatment.

The Goals and Aspirations of the Joint Venture

By establishing a vertically integrated regenerative medicine enterprise that encompasses research and development (R&D), clinical trials, and manufacturing, Visionary Yike Stemcell Technologies is poised to enhance GV's long-term positioning within the North American stem cell market. Gaining insights from Yike’s research and previously established technologies, the joint venture is designed to create innovative, science-based solutions aimed at improving human health and extending longevity.

Xiyong Hou, the CEO of Visionary Holdings, expressed the excitement surrounding this transformative undertaking. He commented, "The establishment of Visionary Yike Stemcell Technologies marks a transformative milestone for GV's global health strategy. Our collaboration aims to leverage cutting-edge regenerative medicine technologies integrated into our commercialization framework to create long-term value for our shareholders."

Future Developments and Expectations

This joint venture is a continuation of GV’s broader strategy that began with a global licensing agreement related to Yike's stem cell technology. It establishes the operational and commercialization backbone necessary to capitalize on the groundbreaking medical technology on a global scale. The joint venture is in line with GV's objective to expand into the healthcare and life sciences sectors effectively.

Regarding the operational infrastructure of the new facility, initial plans include developing state-of-the-art laboratory spaces and manufacturing capabilities that will ensure compliance with the highest industry standards. As the collaboration unfolds, GV and Yike hope to create an integrated campus that advances their mission to bring effective regenerative therapy to market.

Conclusion

In summary, Visionary Holdings and Jiangsu Yike's joint venture stands to redefine the landscape of diabetes treatment through innovative stem cell therapies. With a substantial market opportunity at play and a commitment to excellence evident in both companies, this partnership could very well set a new standard in the field of regenerative medicine. Stakeholders and patients alike can look forward to exciting advancements stemming from this groundbreaking collaboration, potentially leading to significant improvements in health outcomes and quality of life for millions.

Whether through cutting-edge research or innovative solutions targeting chronic diseases, Visionary Yike Stemcell Technologies Inc. aims to be at the forefront of healthcare transformation. As clinical trials commence and research progresses, it remains critical to stay informed about the developments that arise from this promising venture.